Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis.

Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis. We report the case of a 50-year-old woman who was incidentally detected to have essential thrombocytosis after suffering an episode of cerebrovascular accident with faciobrachial monoparesis. She was subsequently initiated on hydroxyurea. Within seven weeks of therapy, the patient noticed irregular hyperpigmented patches over her feet, hands and perioral region, with bluish-grey longitudinal bands on all 20 nails. Hydroxyurea-induced hyperpigmentation and melanonychia are not commonly reported. To the best of our knowledge, this is only the third published report of hydroxyurea-induced hyperpigmentation and melanonychia involving all 20 nails. Physicians need to be aware of such mucocutaneous side effects to avoid misdiagnosis and unwarranted fear in patients. The decision to discontinue the intake of the drug depends heavily on the future risk of thrombotic events.
AuthorsSuman S Karanth, Anurag Gupta, Mukhyaprana Prabhu
JournalSingapore medical journal (Singapore Med J) Vol. 55 Issue 1 Pg. e7-8 (Jan 2014) ISSN: 0037-5675 [Print] Singapore
PMID24452985 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Hydroxyurea
  • Female
  • Humans
  • Hydroxyurea (adverse effects, therapeutic use)
  • Hyperpigmentation (chemically induced)
  • Middle Aged
  • Nail Diseases (chemically induced)
  • Nails (drug effects)
  • Stroke (drug therapy)
  • Thrombocytosis (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: